Long‐term outcome and symptom improvement in patients with interstitial cystitis/bladder pain syndrome with or without regular follow‐up and treatment

Yeh, Hui‐Ling; Jhang, Jia‐Fong; Kuo, Yuh‐Chen; Kuo, Hann‐Chorng

doi:10.1002/nau.24104

Cited by 21 publications

(20 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[14][15][16] However, it is unknown whether the Centering model would be beneficial in ICBPS treatment. Because current ICBPS treatments have limited efficacy and poor adherence, 7,17 there is an urgent need for care models that optimize patient engagement.…”

mentioning

confidence: 99%

“…Interstitial cystitis/bladder pain syndrome (ICBPS) affects up to 10% of women 1,2 and causes stigma and shame, 3,4 compromising patients’ ability to voice their needs. Furthermore, few treatments for ICBPS are widely effective, 5,6 and less than half of patients improve with treatment 7,8 . Women with ICBPS have expressed that novel treatments appeal to them, 6,9 and they also want physicians to address the psychosocial aspects of this disease 3 …”

mentioning

confidence: 99%

See 1 more Smart Citation

Centering Group Treatment for Women With Interstitial Cystitis/Bladder Pain Syndrome: A Qualitative Analysis

Meriwether

Panter

McWethy

et al. 2022

UROGC

View full text Add to dashboard Cite

ImportanceWomen with interstitial cystitis/bladder pain syndrome (ICBPS) face challenging treatment and feelings of isolation. Centering models of group medical visits have been successful in other spheres but have not been explored in ICBPS therapy.ObjectiveWe sought to describe opinions of women with ICBPS regarding Centering visits, including advantages, experience, and barriers to participation and efficacy.Study DesignPatients who attended Centering visits participated in a focus group and/or filled out written commentary in evaluations, and control patients were individually interviewed. We coded transcripts using NVivo software for emergent themes.ResultsWe conducted 4 control patient individual interviews, had one focus group of Centering patients, and collected comments from 34 post-Centering surveys. Emergent themes of interest included motivations and barriers to joining, cost, leadership, connecting with others, diversity, learning, alternative treatments, and areas for improvement. Regardless of participation in Centering, patients noted the importance of self-care and sharing with other women with ICBPS, and they emphasized feelings of isolation in their disease and discouraging health care experiences. Women in Centering noted that the biggest advantages of Centering were learning from other women with ICBPS, the creation of a welcoming and safe space, and the feeling that Centering was more of a support group than a medical visit. Women noted that barriers to Centering included cost and logistical issues, such as time and format.ConclusionsWomen with ICBPS treatment note that Centering group visits provide a sense of learning and community that opens them to a wider variety of options.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Centering Group Treatment for Women With Interstitial Cystitis/Bladder Pain Syndrome: A Qualitative Analysis

Meriwether

Panter

McWethy

et al. 2022

UROGC

View full text Add to dashboard Cite

show abstract

“…Because the pathogenesis of IC/BPS is not well-understood, it is rare for complete resolution of IC/BPS to occur after a single treatment [1]. Currently, most treatments for IC/BPS mainly target symptomatic relief, rather than resolution of disease; however, even satisfactory improvement of symptoms may not be achieved in all patients [49]. Researchers have used BoNT-A for treatment of patients with IC/BPS in clinical trials since 2004, and the initial results of various studies showed promising outcomes [50,51].…”

Section: Resultsmentioning

confidence: 99%

Using Botulinum Toxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome—Possible Pathomechanisms and Practical Issues

Jhang

2019

Toxins

View full text Add to dashboard Cite

Treatment for patients with interstitial cystitis/bladder pain syndrome (IC/BPS) is always challenging for urologists. The main mechanism of the botulinum toxin A (BoNT-A) is inhibition of muscle contraction, but the indirect sensory modulation and anti-inflammatory effect in the bladder also play important roles in treating patients with IC/BPS. Although current guidelines consider BoNT-A injection to be a standard treatment, some practical issues remain debatable. Most clinical evidence of this treatment comes from retrospective uncontrolled studies, and only two randomized placebo-control studies with limited patient numbers have been published. Although 100 U BoNT-A is effective for most patients with IC/BPS, the potential efficacy of 200 U BoNT-A has not been evaluated. Both trigone and diffuse body BoNT-A injections are effective and safe for IC/BPS, although comparison studies are lacking. For IC/BPS patients with Hunner’s lesion, the efficacy of BoNT-A injection remains controversial. Most patients with IC/BPS experience symptomatic relapse at six to nine months after a BoNT-A injection, although repeated injections exhibit a persistent therapeutic effect in long-term follow-up. Further randomized placebo-controlled studies with a larger number of patients are needed to support BoNT-A as standard treatment for patients with IC/BPS.

show abstract

“…Transparency and honesty with the patient about this from the outset are recommended to manage and set realistic expectations. Yeh et al recorded outcomes of BPS patients at long-term follow-up (mean duration 16.6 ± 9.75 years) [ 12 ]. Only 12% achieved a status of being symptom-free, and 47% reported an improvement of at least 50% compared with the baseline.…”

Section: Methodsmentioning

confidence: 99%

Management of Bladder Pain Syndrome (BPS): A Practical Guide

Juliebø‐Jones

Hjelle

Mohn

et al. 2022

Advances in Urology

View full text Add to dashboard Cite

Bladder pain syndrome (BPS) is a prevalent and pervasive disease. The physical and psychological sequelae can be very burdensome for the patient, and the condition represents a real challenge for the clinician as well. With no simple pathognomonic test, finding harmony in navigating patient care can be demanding. Diagnosis and management rely upon a multidisciplinary and holistic approach. Treatment options include conservative measures and pharmacotherapies as well as bladder instillation therapies. Ultimately, surgery may be offered but only in cases of refractory disease. This article offers a pragmatic guide for clinicians managing this challenging disease.

show abstract

Long‐term outcome and symptom improvement in patients with interstitial cystitis/bladder pain syndrome with or without regular follow‐up and treatment

Cited by 21 publications

References 20 publications

Centering Group Treatment for Women With Interstitial Cystitis/Bladder Pain Syndrome: A Qualitative Analysis

Centering Group Treatment for Women With Interstitial Cystitis/Bladder Pain Syndrome: A Qualitative Analysis

Using Botulinum Toxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome—Possible Pathomechanisms and Practical Issues

Management of Bladder Pain Syndrome (BPS): A Practical Guide

Contact Info

Product

Resources

About